1. Home
  2. NIU vs TTRX Comparison

NIU vs TTRX Comparison

Compare NIU & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Niu Technologies

NIU

Niu Technologies

HOLD

Current Price

$3.18

Market Cap

275.6M

ML Signal

HOLD

TTRX

Turn Therapeutics Inc.

N/A

Current Price

$3.65

Market Cap

116.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NIU
TTRX
Founded
2014
2015
Country
China
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
275.6M
116.0M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
NIU
TTRX
Price
$3.18
$3.65
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$8.00
AVG Volume (30 Days)
425.3K
14.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$42.51
N/A
Revenue Next Year
$17.33
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.73
$2.57
52 Week High
$5.67
$5.98

Technical Indicators

Market Signals
Indicator
NIU
TTRX
Relative Strength Index (RSI) 39.44 50.93
Support Level $3.07 $3.55
Resistance Level $3.51 $4.01
Average True Range (ATR) 0.27 0.21
MACD -0.04 0.05
Stochastic Oscillator 4.82 51.47

Price Performance

Historical Comparison
NIU
TTRX

About NIU Niu Technologies

Niu Technologies designs, manufactures and sells high-performance electric motorcycles, scooters, bicycles, and kick-scooters. The company has a product portfolio consisting of electric motorcycle, mopeds and bicycle series, including the NQi, MQi, UQi, F series, and others, and micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. The company's principal operations and geographic markets are predominantly in the People's Republic of China. It also generates revenue from Europe and other regions.

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.

Share on Social Networks: